Cells in tumor microenvironment play critical role in effectiveness of rapalogs

Changing gut microbiome improves outcomes for people newly diagnosed with metastatic kidney cancer in phase I study

People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.

July 05, 2024

Vol.50 No.27

Clinical Roundup

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.

May 31, 2024

Vol.50 No.22

Clinical Roundup

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

May 31, 2024

Vol.50 No.22

Clinical Roundup

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.

April 26, 2024

Vol.50 No.17

Clinical Roundup

siRNA halts ccRCC tumor growth in phase I trial

In a phase I clinical trial led by UT Southwestern Medical Center, a short interfering RNA drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma.

April 26, 2024

Vol.50 No.17

Funding Opportunities

DOD Kidney Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Kidney Cancer Research Program to support research of exceptional scientific merit in the area of kidney cancer.

April 19, 2024

Vol.50 No.16

Cells in tumor microenvironment play critical role in effectiveness of rapalogs

YOU MAY BE INTERESTED IN

Changing gut microbiome improves outcomes for people newly diagnosed with metastatic kidney cancer in phase I study

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

siRNA halts ccRCC tumor growth in phase I trial

DOD Kidney Cancer Research Program funding opportunities for FY24

Renew today!

Subscriber content

Login